PODD
Insulet Corporation NASDAQ Listed May 15, 2007$145.76
+1.56%
vs $143.52
Mkt Cap $10.5B
52w Low $142.43
1.6% of range
52w High $352.82
50d MA $165.09
200d MA $256.42
P/E (TTM)
41.9x
EV/EBITDA
18.3x
P/B
6.8x
Debt/Equity
0.7x
ROE
16.3%
P/FCF
27.7x
RSI (14)
50.80
ATR (14)
$6.17
Beta
1.47
50d MA
$165.09
200d MA
$256.42
Avg Volume
1.6M
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
100 Nagog Park · Acton, MA 01720 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 1.19 | 1.42 | +19.3% | 151.28 | +1.2% | +6.0% | -3.9% | +0.0% | +2.7% | -6.0% | — |
| Feb 18, 2026 | TNS | 1.47 | 1.55 | +5.4% | 258.07 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% | — |
| Nov 6, 2025 | TNS | 1.14 | 1.24 | +8.8% | 323.40 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% | — |
| Aug 7, 2025 | TNS | 0.92 | 1.17 | +27.2% | 303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% | — |
| May 8, 2025 | TNS | 0.79 | 1.02 | +29.1% | 257.00 | +14.0% | +20.9% | +1.9% | -0.7% | +2.2% | +0.2% | — |
| Feb 20, 2025 | TNS | 1.00 | 1.15 | +15.0% | 288.29 | -4.1% | -1.9% | +0.2% | -5.9% | +1.5% | -1.3% | — |
| Nov 7, 2024 | TNS | 0.76 | 0.90 | +18.4% | 244.98 | +4.9% | +9.4% | +2.9% | -0.2% | -2.2% | -2.9% | — |
| Aug 8, 2024 | TNS | 0.56 | 0.55 | -2.5% | 199.79 | -12.8% | -8.8% | +3.2% | +3.5% | -1.6% | +1.8% | — |
| May 9, 2024 | TNS | 0.39 | 0.73 | +87.2% | 177.53 | +2.4% | -6.6% | -2.9% | +7.0% | +4.8% | +2.7% | — |
| Feb 22, 2024 | TNS | 0.66 | 1.40 | +112.1% | 197.14 | -6.2% | -6.6% | -8.3% | -1.3% | -1.8% | +0.2% | — |
| Nov 2, 2023 | TNS | 0.40 | 0.71 | +77.5% | 140.44 | +11.1% | +15.8% | -2.3% | +1.9% | -4.3% | -1.3% | — |
| Aug 8, 2023 | TNS | 0.26 | 0.38 | +46.2% | 238.34 | -1.4% | -3.6% | +1.7% | -3.6% | -0.6% | -2.1% | — |
| May 4, 2023 | BMO | 0.09 | 0.23 | +155.6% | 322.23 | +1.2% | +2.0% | -3.0% | +0.2% | +1.0% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20 | William Blair | Reiterates | Outperform | — | $154.61 | $154.07 | -0.3% | +1.3% | +0.2% | -1.3% | -0.7% | -5.1% |
| Apr 24 | Rothschild & Co | Downgrade | Buy → Neutral | — | $192.21 | $188.85 | -1.7% | -1.4% | -0.7% | -2.9% | -12.5% | +7.6% |
| Apr 24 | Rothschild & Co Redburn | Downgrade | Buy → Neutral | $220 | $192.21 | $188.85 | -1.7% | -1.4% | -0.7% | -2.9% | -12.5% | +7.6% |
| Apr 15 | Truist | Maintains | Buy → Buy | — | $201.49 | $202.82 | +0.7% | +0.5% | -0.5% | +1.1% | -1.4% | -4.3% |
| Apr 9 | Goldman Sachs | Maintains | Buy → Buy | — | $203.51 | $201.67 | -0.9% | -2.0% | -1.2% | +0.4% | +1.9% | +0.5% |
| Apr 7 | Citigroup | Downgrade | Buy → Neutral | — | $203.50 | $200.55 | -1.4% | -0.5% | +0.5% | -2.0% | -1.2% | +0.4% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $238.24 | $236.85 | -0.6% | +0.2% | -1.2% | -6.9% | +2.2% | +2.6% |
| Feb 19 | Citigroup | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Bernstein | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Truist | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Evercore ISI | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Goldman Sachs | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | JP Morgan | Maintains | Overweight → Overweight | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $258.07 | $257.58 | -0.2% | -3.5% | -2.9% | +3.1% | -1.7% | +1.2% |
| Feb 18 | BTIG | Maintains | Buy → Buy | — | $246.34 | $266.00 | +8.0% | +4.8% | -3.5% | -2.9% | +3.1% | -1.7% |
| Feb 4 | Stifel | Maintains | Buy → Buy | — | $251.22 | $253.19 | +0.8% | +0.0% | -3.2% | -0.5% | +1.5% | +2.8% |
| Jan 12 | Barclays | Downgrade | Equal Weight → Underweight | — | $289.04 | $286.71 | -0.8% | -3.6% | -0.1% | +1.7% | +1.3% | +0.4% |
| Jan 9 | Bernstein | Maintains | Outperform → Outperform | — | $292.89 | $293.08 | +0.1% | -1.3% | -3.6% | -0.1% | +1.7% | +1.3% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $289.57 | $292.19 | +0.9% | +1.1% | -1.1% | +0.7% | -2.1% | +1.2% |
| Dec 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $288.73 | $288.81 | +0.0% | +0.3% | +1.1% | -1.1% | +0.7% | -2.1% |
| Nov 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $331.17 | $330.03 | -0.3% | +1.9% | -2.6% | -0.6% | +0.1% | -5.0% |
| Nov 21 | BTIG | Maintains | Buy → Buy | — | $312.89 | $321.96 | +2.9% | +5.8% | +1.9% | -2.6% | -0.6% | +0.1% |
| Nov 21 | Truist | Maintains | Buy → Buy | — | $312.89 | $321.96 | +2.9% | +5.8% | +1.9% | -2.6% | -0.6% | +0.1% |
| Nov 21 | RBC Capital | Maintains | Outperform → Outperform | — | $312.89 | $321.96 | +2.9% | +5.8% | +1.9% | -2.6% | -0.6% | +0.1% |
| Nov 19 | UBS | Upgrade | Neutral → Buy | — | $333.47 | $340.24 | +2.0% | +3.9% | -9.7% | +5.8% | +1.9% | -2.6% |
| Nov 13 | BTIG | Maintains | Buy → Buy | — | $336.84 | $334.87 | -0.6% | -1.2% | +0.0% | -1.4% | +1.7% | +3.9% |
| Nov 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | UBS | Maintains | Neutral → Neutral | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $323.40 | $326.35 | +0.9% | -1.1% | +0.2% | +1.9% | +3.2% | -1.2% |
| Nov 6 | Jefferies | Maintains | Buy → Buy | — | $314.44 | $323.49 | +2.9% | +2.8% | -1.1% | +0.2% | +1.9% | +3.2% |
| Nov 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $320.27 | $315.23 | -1.6% | -1.8% | +2.8% | -1.1% | +0.2% | +1.9% |
| Sep 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $318.00 | $319.60 | +0.5% | -2.3% | -0.6% | -0.9% | +2.0% | -1.0% |
| Sep 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $348.43 | $349.56 | +0.3% | +0.3% | +0.9% | -4.3% | +0.1% | +1.1% |
| Aug 21 | Barclays | Maintains | Equal Weight → Equal Weight | — | $333.00 | $332.23 | -0.2% | -1.5% | +0.9% | -0.5% | +0.9% | +0.8% |
| Aug 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $303.55 | $303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $303.55 | $303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $303.55 | $303.55 | +0.0% | +1.2% | -0.7% | +1.6% | -0.3% | +2.3% |
| May 27 | Raymond James | Maintains | Outperform → Outperform | — | $321.36 | $325.00 | +1.1% | +1.6% | -0.9% | +0.1% | +0.4% | -0.0% |
| May 22 | Citigroup | Maintains | Buy → Buy | — | $324.50 | $324.00 | -0.2% | -1.1% | +0.1% | +1.6% | -0.9% | +0.1% |
| May 13 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $316.67 | $316.67 | +0.0% | -0.7% | +2.2% | +0.2% | +0.8% | +0.3% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $257.00 | $293.03 | +14.0% | +20.9% | +1.9% | -0.7% | +2.2% | +0.2% |
| Apr 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $251.27 | $249.55 | -0.7% | +0.4% | -0.8% | +2.7% | +0.7% | +0.0% |
| Apr 29 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $259.52 | $255.65 | -1.5% | -3.2% | +0.4% | -0.8% | +2.7% | +0.7% |
| Feb 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $288.29 | $276.35 | -4.1% | -1.9% | +0.2% | -5.9% | +1.5% | -1.3% |
| Feb 21 | Raymond James | Maintains | Outperform → Outperform | — | $288.29 | $276.35 | -4.1% | -1.9% | +0.2% | -5.9% | +1.5% | -1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | BORIO LUCIANADir | — | Sell | 418 | $143.27 | $60K | 4,329 | +4.65% | -1.01% |
| Jun 3, 2026 | STONESIFER TIMOTHY C.Dir | — | Buy | 2,790 | $143.51 | $400K | 9,041 | +4.65% | -1.01% |
| Jun 3, 2026 | WEATHERMAN ELIZABETH HDir | — | Buy | 3,450 | $144.20 | $497K | 10,352 | +2.17% | -5.58% |
8-K · 7.01
! Medium
Insulet Corporation -- 8-K 7.01: Regulation FD Disclosure
Insulet Corporation disclosed information regarding a voluntary medical device correction separate from a previously announced March 12, 2026 action, though specific details of the new disclosure were not provided in this filing.
May 26
8-K · 7.01
! Medium
Insulet Corporation -- 8-K 7.01: Regulation FD Disclosure
Insulet Corporation disclosed 18 serious adverse event reports related to its insulin pump devices, prompting a customer communication update on April 10, 2026, which may impact investor confidence and regulatory standing.
Apr 29
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Insulet Corporation disclosed forward-looking statements with standard cautionary language, indicating management won't proactively update projections unless legally required, so investors should independently reassess PODD's outlook regularly.
Mar 12
8-K · 5.02
!!! Very High
Insulet Corporation -- 8-K 5.02: Executive Change
Insulet Corporation's former CFO Chadwick departed under standard severance terms previously disclosed, with no additional material compensation beyond existing plan provisions.
Mar 4
8-K · 4.01
!!! Very High
Insulet Corporation -- 8-K 4.01: Auditor Change / Resignation
Insulet Corporation (PODD) replaced auditor GT with PwC for fiscal 2026, a routine transition that suggests no material accounting disputes and maintains audit oversight continuity.
Feb 24
8-K
Insulet Corporation -- 8-K Filing
Insulet completed a $60 million share repurchase and plans approximately $300 million in repurchases during Q1 2026, signaling management confidence and commitment to returning capital to shareholders.
Feb 18
8-K · 1.01
!! High
Insulet Corporation -- 8-K 1.01: Material Agreement
Insulet Corporation extended its existing supply agreement with NXP USA through a 2026 addendum, securing continued semiconductor components for its insulin pump devices.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 4,579,274 | $961M | New | Mar 2026 |
| 2 | Fmr Llc | 3,974,712 | $834M | Reduced | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 3,449,987 | $724M | New | Mar 2026 |
| 4 | Morgan Stanley | 2,269,166 | $645M | Reduced | Dec 2025 |
| 5 | Capital Research Global Investors | 1,669,556 | $350M | Reduced | Mar 2026 |
| 6 | Aqr Capital Management Llc | 1,598,724 | $335M | Added | Mar 2026 |
| 7 | Clearbridge Investments, Llc | 1,321,026 | $277M | Reduced | Mar 2026 |
| 8 | Arrowstreet Capital, Limited Partnership | 1,229,928 | $258M | Added | Mar 2026 |
| 9 | Invesco Ltd. | 1,096,537 | $230M | Reduced | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 762,349 | $160M | Added | Mar 2026 |
| 11 | Man Group Plc | 716,426 | $150M | Added | Mar 2026 |
| 12 | Jupiter Asset Management Ltd | 709,902 | $149M | Added | Mar 2026 |
| 13 | Northern Trust Corp | 693,817 | $146M | Reduced | Mar 2026 |
| 14 | Artisan Partners Limited Partnership | 692,974 | $145M | Added | Mar 2026 |
| 15 | Qube Research & Technologies Ltd | 641,676 | $135M | Added | Mar 2026 |
| 16 | Marshall Wace, Llp | 606,482 | $127M | Added | Mar 2026 |
| 17 | Soleus Capital Management, L.p. | 562,500 | $118M | Added | Mar 2026 |
| 18 | Nordea Investment Management Ab | 557,290 | $116M | Added | Mar 2026 |
| 19 | Voya Investment Management Llc | 400,870 | $114M | Added | Dec 2025 |
| 20 | Amundi | 446,918 | $94M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$10.48B
Enterprise Value
$10.74B
P/E (TTM)
41.89x
Forward P/E
22.93x
PEG Ratio
-1.96x
P/B
6.77x
P/S
3.87x
P/FCF
27.74x
EV/EBITDA
18.30x
Shares Out
71.9M
Financials (TTM)
Revenue
$2.71B
Net Income
$247.1M
EBITDA
$586.9M
Free Cash Flow
$377.7M
Op Cash Flow
$569.3M
EPS Basic
$3.51
EPS Diluted
$3.48
EPS Forward
$6.36
Gross Margin
71.6%
Op Margin
17.5%
Net Margin
9.1%
Balance Sheet
Total Assets
$3.19B
Total Liab.
$1.68B
Total Equity
$1.52B
Cash
$716.1M
LT Debt
$979.7M
Book Value/Sh
$21.54
Debt/Equity
0.69x
Current Ratio
2.78
Quick Ratio
2.11
Returns & Growth
ROE
16.3%
ROA
7.8%
ROIC
13.6%
Rev Growth YoY
+30.7%
EPS Growth YoY
-41.2%
Price Returns
2W
-2.5%
1M
-15.8%
3M
-41.2%
6M
-55.7%
12M
-55.4%
Technicals
52W High
$352.82
52W Low
$142.43
50d MA
$165.09
200d MA
$256.42
RSI (14)
50.80
ATR (14)
$6.17
Beta
1.47
Avg Volume
1.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$339.00
High
$435.00
Low
$220.00
Median
$330.00
Data updated apr 26, 2026 8:20pm
· Source: financialmodelingprep.com